Tumor immunosurveillance in human cancers.
Until now, the anatomic extent of tumor (TNM classification) has been by far the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients' disease-free and overall survival. Tumoral and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. The density and the immune cell location within the tumor have a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host-immune reaction. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice.
INSERM U872, Integrative Cancer Immunology Team, 15 rue de l'Ecole de Médecine, Paris 75006, France.
Bernhard
B
Mlecnik
Gabriela
G
Bindea
Franck
F
Pagès
Jérôme
J
Galon
D006801:Humans; D007107:Immune System / Q000276:immunology; D007156:Immunologic Memory; D007157:Immunologic Surveillance; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D013601:T-Lymphocytes / Q000276:immunology; D059016:Tumor Microenvironment / Q000276:immunology
Clin Cancer Res. 2005 Mar 1;11(5):1791-7
15756001
Oncogene. 2004 Feb 19;23(7):1377-91
14973550
N Engl J Med. 2003 Feb 6;348(6):567-8
12571271
Cancer Res. 2001 May 15;61(10):3932-6
11358808
N Engl J Med. 2008 Jun 19;358(25):2704-15
18565863
Int J Cancer. 2005 Jun 10;115(2):256-62
15688387
J Clin Oncol. 2009 Jun 1;27(16):2583-5
19364958
Respir Med. 2010 Oct;104(10):1543-50
20580882
Semin Cancer Biol. 2001 Aug;11(4):277-83
11513563
Cancer Biol Ther. 2007 Sep;6(9):1496-504
17881897
Biochim Biophys Acta. 2007 Jan;1775(1):103-37
17010523
Nature. 2010 Oct 28;467(7319):1114-7
20981102
Nature. 2010 Oct 28;467(7319):1109-13
20981101
Gastroenterology. 2010 Apr;138(4):1429-40
19909745
Adv Immunol. 2006;90:1-50
16730260
J Surg Oncol. 2006 Jul 1;94(1):68-80
16788948
J Clin Pathol. 1986 Jun;39(6):585-9
3722412
Nat Rev Cancer. 2007 Nov;7(11):834-46
17957189
J Clin Oncol. 2006 Nov 20;24(33):5313-27
17060676
Lab Invest. 2005 Sep;85(9):1118-29
15980885
J Surg Oncol. 2005 Dec 15;92(4):347-59
16299807
Nature. 2007 Dec 6;450(7171):903-7
18026089
Bioinformatics. 2009 Apr 15;25(8):1091-3
19237447
J Cell Mol Med. 2008 Apr;12(2):374-90
18182063
N Engl J Med. 2003 Jan 16;348(3):203-13
12529460
Science. 2006 Sep 29;313(5795):1960-4
17008531
Br J Cancer. 1984 Mar;49(3):375-7
6704315
Genes Chromosomes Cancer. 1999 Apr;24(4):306-14
10092128
Nature. 2001 Apr 26;410(6832):1107-11
11323675
J Clin Pathol. 1989 Feb;42(2):162-6
2921357
Lancet. 2005 Jan 8-14;365(9454):153-65
15639298
Nat Rev Cancer. 2008 Apr;8(4):299-308
18354418
Curr Opin Immunol. 2010 Apr;22(2):215-22
20207124
Nat Rev Immunol. 2006 Nov;6(11):836-48
17063185
J Pathol. 2004 Sep;204(1):65-74
15307139
Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72
18402523
J Gastroenterol. 2006 Mar;41(3):185-92
16699851
Cancer Res. 2009 Mar 15;69(6):2685-93
19258510
Science. 2001 Nov 9;294(5545):1343-6
11598267
J Clin Invest. 2001 Aug;108(4):577-83
11518731
J Immunol. 1999 Oct 1;163(7):3676-83
10490962
Cancer Res. 2007 Mar 1;67(5):1883-6
17332313
Dis Colon Rectum. 2004 Feb;47(2):141-52
15043283
Cancer Res. 2001 Nov 1;61(21):7792-7
11691794
J Surg Res. 2005 Apr;124(2):216-24
15820251
C R Biol. 2003 Oct-Nov;326(10-11):1041-3
14744111
J Clin Oncol. 2011 Feb 20;29(6):610-8
21245428
Cancer Res. 2002 Feb 15;62(4):1139-47
11861395
N Engl J Med. 2005 Dec 22;353(25):2654-66
16371631
Oncogene. 2005 Sep 8;24(40):6155-64
16091735
Anticancer Res. 2009 Feb;29(2):465-8
19331187
Cancer Res. 1998 Aug 15;58(16):3491-4
9721846
Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57
12672517
J Clin Oncol. 2009 Dec 10;27(35):5944-51
19858404
Oncogene. 2010 Feb 25;29(8):1093-102
19946335
Annu Rev Immunol. 2004;22:329-60
15032581
Gastroenterology. 2005 Sep;129(3):874-84
16143127
Oncogene. 2008 Jan 7;27(2):190-9
18176600
J Clin Oncol. 2004 May 1;22(9):1564-71
15051756
Clin Cancer Res. 2003 Nov 15;9(15):5607-15
14654542
Cancer Immun. 2009 Feb 19;9:1
19226101
Annu Rev Immunol. 2004;22:745-63
15032595
Melanoma Res. 2009 Oct;19(5):275-82
19633580
Gut. 1979 Oct;20(10):868-74
533699
Int J Cancer. 1995 Jan 17;60(2):183-9
7829213
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5
14665696
Cancer. 1996 Apr 1;77(7):1303-10
8608507